Our mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia.
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.
Learn About Our WorkMeet Our Team
Read our latest news
December 2, 2025
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
April 8, 2025
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
Learn More
Contact Us
50 Beharrell St, Unit B
Concord, MA 01742